RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, IMGN, PCVX, LEGN, RYTM, and represent 48.34% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: IMGN (+$309M), MGNX (+$36M), CCCC (+$28M), URGN (+$24M), GPCR (+$20M), ARVN (+$17M), HARP (+$17M), RXST (+$14M), THRD (+$12M), WVE (+$5.1M).
- Started 5 new stock positions in GPCR, ARVN, CCCC, Sab Biotherapeutics, HARP.
- Reduced shares in these 10 stocks: ASND (-$77M), COGT (-$63M), SLNO (-$37M), RNA (-$36M), CVAC (-$33M), VRDN (-$31M), ACRS (-$30M), EYPT (-$27M), RYTM (-$16M), CELC (-$13M).
- Sold out of its positions in ACRS, CELC, COGT, EYPT, NSTG, NKTR, SLNO, Talaris Therapeutics, VRDN.
- Ra Capital Management was a net buyer of stock by $71M.
- Ra Capital Management has $6.4B in assets under management (AUM), dropping by 26.04%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Ra Capital Management
Ra Capital Management holds 62 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Ascendis Pharma A/s - SH (ASND) | 19.9 | $1.3B | -5% | 10M | 125.95 |
|
Immunogen SH (IMGN) | 11.0 | $704M | +78% | 24M | 29.65 |
|
Vaxcyte SH (PCVX) | 7.7 | $496M | 7.9M | 62.80 |
|
|
Legend Biotech Corp- SH (LEGN) | 5.9 | $377M | 6.3M | 60.17 |
|
|
Rhythm Pharmaceuticals SH (RYTM) | 3.8 | $245M | -6% | 5.3M | 45.97 |
|
Aerovate Therapeutics SH (AVTE) | 2.9 | $187M | 8.3M | 22.63 |
|
|
Inhibrx SH (INBX) | 2.8 | $180M | 4.7M | 38.00 |
|
|
Cymabay Therapeutics SH (CBAY) | 2.6 | $164M | 6.9M | 23.62 |
|
|
Biogen SH (BIIB) | 2.2 | $138M | 533k | 258.77 |
|
|
Rxsight SH (RXST) | 2.1 | $137M | +11% | 3.4M | 40.32 |
|
89bio SH (ETNB) | 2.0 | $128M | 11M | 11.17 |
|
|
Verona Pharma Plc - SH (VRNA) | 2.0 | $126M | 6.3M | 19.88 |
|
|
Day One Biopharmaceuticals I SH (DAWN) | 1.8 | $114M | 7.8M | 14.60 |
|
|
An2 Therapeutics SH (ANTX) | 1.8 | $114M | 5.6M | 20.49 |
|
|
Tyra Biosciences SH (TYRA) | 1.6 | $100M | 7.2M | 13.85 |
|
|
Janux Therapeutics SH (JANX) | 1.5 | $98M | 9.2M | 10.73 |
|
|
Geron Corp SH (GERN) | 1.5 | $98M | 46M | 2.11 |
|
|
Icosavax SH (ICVX) | 1.5 | $94M | 6.0M | 15.76 |
|
|
Alpine Immune Sciences SH (ALPN) | 1.5 | $94M | +4% | 4.9M | 19.06 |
|
Wave Life Sciences SH (WVE) | 1.4 | $92M | +5% | 18M | 5.05 |
|
Newamsterdam Pharma Co Nv SH (NAMS) | 1.4 | $88M | -12% | 7.9M | 11.17 |
|
4d Molecular Therapeutics In SH (FDMT) | 1.3 | $84M | 4.2M | 20.26 |
|
|
Evolent Health Inc - A SH (EVH) | 1.3 | $84M | -6% | 2.5M | 33.03 |
|
Axsome Therapeutics SH (AXSM) | 1.2 | $80M | 1.0M | 79.59 |
|
|
Fulcrum Therapeutics SH (FULC) | 1.2 | $78M | 12M | 6.75 |
|
|
Cytek Biosciences SH (CTKB) | 1.0 | $62M | 6.8M | 9.12 |
|
|
Acumen Pharmaceuticals SH (ABOS) | 0.9 | $57M | 15M | 3.84 |
|
|
Pepgen SH (PEPG) | 0.9 | $55M | 8.1M | 6.80 |
|
|
Apogee Therapeutics SH (APGE) | 0.9 | $55M | 2.0M | 27.94 |
|
|
Ars Pharmaceuticals SH (SPRY) | 0.8 | $52M | 9.5M | 5.48 |
|
|
Nkarta SH (NKTX) | 0.8 | $52M | 7.8M | 6.60 |
|
|
Vor Biopharma SH (VOR) | 0.8 | $51M | 23M | 2.25 |
|
|
Iteos Therapeutics SH (ITOS) | 0.8 | $48M | 4.4M | 10.95 |
|
|
Madrigal Pharmaceuticals SH (MDGL) | 0.7 | $47M | 205k | 231.38 |
|
|
Urogen Pharma SH (URGN) | 0.7 | $46M | +107% | 3.1M | 15.00 |
|
Macrogenics SH (MGNX) | 0.6 | $39M | +1085% | 4.1M | 9.62 |
|
Eliem Therapeutics SH (ELYM) | 0.6 | $36M | 13M | 2.70 |
|
|
Taysha Gene Therapies SH (TSHA) | 0.5 | $33M | 19M | 1.77 |
|
|
Gh Research SH (GHRS) | 0.5 | $32M | 5.6M | 5.80 |
|
|
Enliven Therapeutics SH (ELVN) | 0.5 | $29M | 2.1M | 13.84 |
|
|
C4 Therapeutics SH (CCCC) | 0.4 | $28M | NEW | 4.9M | 5.65 |
|
Mineralys Therapeutics SH (MLYS) | 0.4 | $27M | 3.2M | 8.60 |
|
|
Werewolf Therapeutics SH (HOWL) | 0.4 | $24M | 6.1M | 3.86 |
|
|
Acrivon Therapeutics SH (ACRV) | 0.4 | $24M | 4.8M | 4.92 |
|
|
Pliant Therapeutics SH (PLRX) | 0.4 | $23M | -27% | 1.3M | 18.11 |
|
Third Harmonic Bio SH (THRD) | 0.3 | $22M | +111% | 2.0M | 10.97 |
|
Avidity Biosciences SH (RNA) | 0.3 | $22M | -61% | 2.5M | 9.05 |
|
Solid Biosciences SH (SLDB) | 0.3 | $21M | 3.4M | 6.14 |
|
|
Structure Therapeutics SH (GPCR) | 0.3 | $20M | NEW | 487k | 40.76 |
|
Tenaya Therapeutics SH (TNYA) | 0.3 | $18M | -18% | 5.5M | 3.24 |
|
Arvinas SH (ARVN) | 0.3 | $17M | NEW | 421k | 41.16 |
|
Harpoon Therapeutics SH (HARP) | 0.3 | $17M | NEW | 1.5M | 11.37 |
|
Bicycle Therapeutics Plc- SH (BCYC) | 0.2 | $15M | 800k | 18.08 |
|
|
Curevac Nv SH (CVAC) | 0.2 | $12M | -74% | 2.7M | 4.21 |
|
Compass Pathways SH (CMPS) | 0.2 | $11M | 1.3M | 8.75 |
|
|
Black Diamond Therapeutics I SH (BDTX) | 0.2 | $9.9M | 3.5M | 2.81 |
|
|
Chimerix SH (CMRX) | 0.1 | $8.5M | +35% | 8.8M | 0.96 |
|
Igm Biosciences SH (IGMS) | 0.1 | $7.8M | 938k | 8.31 |
|
|
Connect Biopharma Holdings L SH (CNTB) | 0.1 | $3.6M | -56% | 3.1M | 1.18 |
|
Unicycive Therapeutics SH (UNCY) | 0.0 | $3.0M | 3.5M | 0.87 |
|
|
Sab Biotherapeutics SH | 0.0 | $1.6M | NEW | 2.4M | 0.69 |
|
Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.0 | $1.0M | 333k | 3.13 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022
- Ra Capital Management 2022 Q1 filed May 16, 2022
- Ra Capital Management 2021 Q4 filed Feb. 14, 2022
- Ra Capital Management 2021 Q3 filed Nov. 15, 2021
- Ra Capital Management 2021 Q2 filed Aug. 16, 2021
- Ra Capital Management 2021 Q1 filed May 17, 2021
- Ra Capital Management 2020 Q4 filed Feb. 16, 2021
- Ra Capital Management 2020 Q3 filed Nov. 16, 2020
- Ra Capital Management 2020 Q2 filed Aug. 14, 2020